RU2002135586A - COSMETIC COMPOSITIONS, INCLUDING HUMAN SERUM ALBUMIN, OBTAINED FROM TRANSGENIC ANIMALS NOT A HUMAN - Google Patents

COSMETIC COMPOSITIONS, INCLUDING HUMAN SERUM ALBUMIN, OBTAINED FROM TRANSGENIC ANIMALS NOT A HUMAN

Info

Publication number
RU2002135586A
RU2002135586A RU2002135586/15A RU2002135586A RU2002135586A RU 2002135586 A RU2002135586 A RU 2002135586A RU 2002135586/15 A RU2002135586/15 A RU 2002135586/15A RU 2002135586 A RU2002135586 A RU 2002135586A RU 2002135586 A RU2002135586 A RU 2002135586A
Authority
RU
Russia
Prior art keywords
hsa
cosmetic composition
weight
range
human
Prior art date
Application number
RU2002135586/15A
Other languages
Russian (ru)
Other versions
RU2247554C2 (en
Inventor
Вольфрам Айхнер
Клаус Зоммермейер
Original Assignee
Фрезениус Каби Дойчланд Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10026998A external-priority patent/DE10026998A1/en
Application filed by Фрезениус Каби Дойчланд Гмбх filed Critical Фрезениус Каби Дойчланд Гмбх
Publication of RU2002135586A publication Critical patent/RU2002135586A/en
Application granted granted Critical
Publication of RU2247554C2 publication Critical patent/RU2247554C2/en

Links

Claims (19)

1. Способ получения косметической композиции, включающей HSA, где (a) HSA получают из трансгенного животного, не являющегося человеком, и (b) HSA смешивают с подходящим носителем и/или адъювантом.1. A method of obtaining a cosmetic composition comprising HSA, where (a) HSA is obtained from a transgenic non-human animal, and (b) HSA is mixed with a suitable carrier and / or adjuvant. 2. Способ по п.1, где HSA получают из крупного рогатого скота, овец, свиней, лошадей, грызунов или коз.2. The method according to claim 1, where the HSA is obtained from cattle, sheep, pigs, horses, rodents or goats. 3. Способ по п.1 или 2, где HSA получают из молока или крови трансгенного животного, не являющегося человеком.3. The method according to claim 1 or 2, where the HSA is obtained from milk or blood of a transgenic non-human animal. 4. Способ по одному из пп.1-3, где HSA получают из молока лактирующей коровы.4. The method according to one of claims 1 to 3, where the HSA is obtained from milk of a lactating cow. 5. Способ по п.1 или 2, где HSA получают из яйца трансгенной птицы.5. The method according to claim 1 or 2, where the HSA is obtained from an egg of a transgenic bird. 6. Способ по любому из предшествующих пунктов, где стадия получения HSA включает стадию очистки.6. The method according to any one of the preceding paragraphs, wherein the HSA production step comprises a purification step. 7. Способ по п.6, где очистка проводится путем фильтрации.7. The method according to claim 6, where the cleaning is carried out by filtration. 8. Способ по одному из пп.1-7, где стадия получения HSA включает преципитацию HSA из раствора, содержащего HSA.8. The method according to one of claims 1 to 7, where the step of producing HSA includes precipitation of HSA from a solution containing HSA. 9. Способ по любому из пп.1-8, где стадия получения HSA, кроме того, включает стадию хроматографической очистки.9. The method according to any one of claims 1 to 8, wherein the step of producing HSA further comprises a step of chromatographic purification. 10. Способ по п.9, где стадию хроматографии проводят путем аффинной или ионообменной хроматографии.10. The method according to claim 9, where the stage of chromatography is carried out by affinity or ion exchange chromatography. 11. Способ по любому из пп.1-10, где HSA, выделенный из трансгенных животных, не являющихся человеком, включает остаточное количество BSA в пределах 0-10% по массе от выделенного HSA.11. The method according to any one of claims 1 to 10, wherein the HSA isolated from non-human transgenic animals comprises a residual amount of BSA in the range of 0-10% by weight of the isolated HSA. 12. Способ по п.11, где остаточное количество BSA находится в пределах 0,05-2,5% по массе от выделенного HSA.12. The method according to claim 11, where the residual amount of BSA is in the range of 0.05-2.5% by weight of the allocated HSA. 13. Способ по п.12, где остаточное количество BSA находится в пределах 0,5-1,0% по массе от выделенного HSA.13. The method according to item 12, where the residual amount of BSA is in the range of 0.5-1.0% by weight of the allocated HSA. 14. Способ по любому из пп.1-13, где HSA включен в косметическую композицию в концентрации, лежащей в пределах от 0,1 до 30% по массе от косметической композиции.14. The method according to any one of claims 1 to 13, where HSA is included in the cosmetic composition in a concentration lying in the range from 0.1 to 30% by weight of the cosmetic composition. 15. Способ по п.14, где HSA включен в косметическую композицию в концентрации, лежащей в пределах от 1 до 15% по массе от косметической композиции.15. The method according to 14, where the HSA is included in the cosmetic composition in a concentration lying in the range from 1 to 15% by weight of the cosmetic composition. 16. Способ по п.15, где HSA включен в косметическую композицию в концентрации, лежащей в пределах от 3 до 8% по массе от косметической композиции.16. The method according to clause 15, where the HSA is included in the cosmetic composition in a concentration lying in the range from 3 to 8% by weight of the cosmetic composition. 17. Косметическая композиция, полученная способом по любому из пп.1-16.17. Cosmetic composition obtained by the method according to any one of claims 1 to 16. 18. Косметическая композиция по п.17, которая представляет собой лосьон, крем, гель или масло.18. The cosmetic composition according to 17, which is a lotion, cream, gel or oil. 19. Применение композиции по одному из п.17 или 18 для косметического лечения морщин, шрамов и ожоговых ран.19. The use of the composition according to one of p. 17 or 18 for the cosmetic treatment of wrinkles, scars and burn wounds.
RU2002135586/15A 2000-05-31 2001-05-28 Cosmetic compositions including human serum albumin obtained out of transgenic animals, not out of men RU2247554C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10026998A DE10026998A1 (en) 2000-05-31 2000-05-31 Process for the preparation of a cosmetic composition comprising human serum albumin obtained from transgenic non-human mammals
DE10026998.2 2000-05-31

Publications (2)

Publication Number Publication Date
RU2002135586A true RU2002135586A (en) 2004-04-10
RU2247554C2 RU2247554C2 (en) 2005-03-10

Family

ID=7644237

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002135586/15A RU2247554C2 (en) 2000-05-31 2001-05-28 Cosmetic compositions including human serum albumin obtained out of transgenic animals, not out of men

Country Status (15)

Country Link
US (1) US20040223988A1 (en)
EP (1) EP1289492A1 (en)
JP (1) JP2003534363A (en)
CN (1) CN1241540C (en)
AU (2) AU7054001A (en)
BR (1) BR0111272A (en)
CA (1) CA2409921A1 (en)
DE (2) DE10026998A1 (en)
ES (1) ES2190908T1 (en)
MX (1) MXPA02011736A (en)
NO (1) NO20025604L (en)
NZ (1) NZ522669A (en)
RU (1) RU2247554C2 (en)
TR (1) TR200300447T3 (en)
WO (1) WO2001091713A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787636B1 (en) 2000-07-14 2004-09-07 New Century Pharmaceuticals, Inc. Modified serum albumin with reduced affinity for nickel and copper
US7829072B2 (en) * 2000-07-14 2010-11-09 Carter Daniel C Serum albumin compositions for use in cleansing or dermatological products for skin or hair
CA2774959C (en) 2000-08-04 2016-05-31 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
CN101172091B (en) 2007-09-25 2011-04-27 北京美福源生物医药科技有限公司 Technique for preparing amalgamation protein skin-protection product containing albuminar and skin cell growth factor, and uses of the same
EP2799114A3 (en) 2003-05-15 2015-02-18 Ampio Pharmaceuticals, Inc. Treatment of T-cell mediated diseases
DE10348022A1 (en) * 2003-10-15 2005-05-25 Imtm Gmbh New dipeptidyl peptidase IV inhibitors for the functional influence of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases
RU2366469C2 (en) 2007-10-02 2009-09-10 Константин Станиславович Авраменко Tattoo or scar removal technique
WO2009146320A1 (en) 2008-05-27 2009-12-03 Dmi Life Sciences, Inc. Therapeutic methods and compounds
US20100008885A1 (en) * 2008-07-09 2010-01-14 Susan Daly Methods and kits imparting benefits to keratin-containing substrates
US8507496B2 (en) 2010-09-07 2013-08-13 Dmi Acquisition Corp. Treatment of diseases
PL2766029T3 (en) 2011-10-10 2020-08-24 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
AU2012323320B2 (en) 2011-10-10 2017-05-11 Ampio Pharmaceuticals, Inc. Implantable medical devices with increased immune tolerance, and methods for making and implanting
JP6231484B2 (en) 2011-10-28 2017-11-15 アンピオ ファーマシューティカルズ，インコーポレイテッド Rhinitis treatment
JP6588005B2 (en) 2013-03-15 2019-10-09 アンピオ ファーマシューティカルズ，インコーポレイテッド Pharmaceutical composition used to stimulate cartilage formation
CN104207959B (en) * 2013-06-05 2018-06-26 陈慧敏 A kind of eye compacts Essence
EP4066836A1 (en) 2014-08-18 2022-10-05 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
WO2016209969A1 (en) 2015-06-22 2016-12-29 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
CN105534848B (en) * 2015-12-29 2018-11-02 四川新生命干细胞科技股份有限公司 A kind of cosmetics or medical composition and its use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2570605B1 (en) * 1984-09-26 1987-05-22 Gerard Laumond USEFUL COMPOSITION IN COSMETOLOGY
ZA858074B (en) * 1984-11-06 1986-06-25 Exovir Inc Antiwrinkle cosmetic preparation
CA2351200A1 (en) * 1989-12-01 1991-06-13 Gene Pharming Europe Bv Production of recombinant polypeptides by bovine species and transgenic methods
GB9414651D0 (en) * 1994-07-20 1994-09-07 Gene Pharming Europ Bv Separation of human serum albumin
PE99498A1 (en) * 1996-07-26 1999-01-21 Novartis Ag FUSION POLYPEPTIDES

Similar Documents

Publication Publication Date Title
RU2002135586A (en) COSMETIC COMPOSITIONS, INCLUDING HUMAN SERUM ALBUMIN, OBTAINED FROM TRANSGENIC ANIMALS NOT A HUMAN
Sorvari et al. Bursa Fabricii as a peripheral lymphoid organ: transport of various materials from the anal lips to the bursal lymphoid follicles with reference to its immunological
ATE271783T1 (en) METHOD FOR PRODUCING A PROTEIN COMPOSITION AND AN INFANT FOOD CONTAINING SAME
Hemmings et al. Transport of large breakdown products of dietary protein through the gut wall.
EP0143445A3 (en) Process for obtaining transfer factor from colostrum, transfer factor so obtained and use thereof
CA2073166C (en) Process to correct and optimize the composition of a feed
FI882707A (en) PREPARATION OF THE PREPARATION FOR THE PREPARATION OF THE PROTEINS.
ATE164760T1 (en) PREPARATION FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS FOR RUMINANTS
IT7869491A0 (en) PROCEDURE AND DEVICE FOR THE ELIMINATION OF THE APPENDAGES PARTICULARLY FOR TRIMMING THE BEAKS OF POULTRY SPECIES
IL68350A0 (en) N-glycosylated carboxamide derivatives,their preparation and their use for the treatment of animals
MXPA02011736A (en) Cosmetic composition comprising human serum albumin obtained from transgenic non-human animals.
ATE247379T1 (en) METHOD FOR AUTOMATIC MILKING OF ANIMALS AND A FULLY AUTOMATIC MILKING MACHINE WITH A MILKING ROBOT SUITABLE FOR CARRYING OUT THIS METHOD
Molik et al. The effect of the photoperiod and exogenous melatonin on the protein content in sheep milk
DE69100607D1 (en) Composition for the manufacture of artificial milk for calves and artificial milk for calves made therefrom.
Reiter et al. Lactation in horses
BR0214702A (en) Methods and compositions for pet breeding employment
RU94028857A (en) Crossing animal selection method
EP0127712B1 (en) Deodorant containing bacterial antibodies
FI913566A0 (en) OEKAD PROTEINPRODUKTION I DJUR.
JP4656300B2 (en) Method for producing immunoregulatory protein
Eisa et al. Variations in milk yield and composition between fore and rear udder-halves in she-camel (Camelus dromedarius)
Iloeje Components of variance for growth traits among Zebu and South Devon beef cattle in southeastern Nigeria
Bignami et al. Effect of the health status in late pregnancy on the concentration of the immunoglobulin in the colostrum of dairy cows.
JP2001011094A5 (en)
Puppel et al. Changes in colostrum bioactive components depend on cytological quality